1. Kennedy, A et al; An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition and killing of CD20 cells by rituximab. Blood 2003, 101:3
2. Kennedy, A et al; Rituximab infusion promotes rapid complement depletion and acute CD20 loss in Chronic Lymphocytic Leukemia. Journal of Immunology 2004, 172:5
3. Pawluczkowycz, A et al; Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: Potential implications for the pathogenesis of anemia in malaria. Journal of Immunology 2007, 178:8
4. Risitano, AM; Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 2012, 217:11
5. Lindorfer, M et al; A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 2010, 115:11
6. DiLillo, D et al; Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Molecular Immunology 2006, 43:7
7. PaixA￡o-Cavalvante, D et al; A humanized antibody that regulates the alternative pathway convertase: Potential for therapy of renal disease associated with nephritic factors. Journal of Immunology 2014, 192:10
8. Beum, P et al; Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. Journal of immunology 2008, 181:1

1. Frei, Y et al; Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol Cell Probes 1987, 1: 141
2. Thurman, J et al; C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ischemia/reperfusion. J Immunol 2007, 178: 1819
3. Mihai, S et al; The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol 2007, 178: 6514
4. Wang, H et al; Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007, 179: 4451
5. Huugen, D et al; Inhibition of complement factor C5 protects against antimyeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007, 71: 646
6. Nilsson, K et al. Enhanced susceptibility to low-dose collagen-induced arthritis in CR1/2-deficient female mice ?“ possible role of estrogen on CR1 expression. Faseb 2009, 23: 2450
7. Copland, D et al. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clin exp immunol 2010, 159:303
8. Pavlovski, D et al; Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis, Faseb 2012, 26: 3680

1. Blatt A et al; Properdin-mediated C5a production enhances stable binding of platelets to granulocytes in human whole blood. J Immunol 2016; 196: 4671

1. Lindorfer, M et al; A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 2010, 115:11